Durable remissions with obinutuzumab-based chemoimmunotherapy: Long-term follow-up of the phase 1b GALTON trial in CLL

Jennifer R. Brown; Susan OBrien; C. Daniel Kingsley; Herbert Eradat; John M. Pagel; Jamie Hirata; Tammy McIver; Rodica Morariu-Zamfir; Thomas J. Kipps

doi:10.1182/blood-2018-06-857714

Durable remissions with obinutuzumab-based chemoimmunotherapy: Long-term follow-up of the phase 1b GALTON trial in CLL

Jennifer R. Brown
, Susan OBrien
, C. Daniel Kingsley
, Herbert Eradat
, John M. Pagel
, Jamie Hirata
, Tammy McIver
, Rodica Morariu-Zamfir
, Thomas J. Kipps

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English
Pages (from-to)	990-992
Number of pages	3
Journal	Blood
Volume	133
Issue number	9
DOIs	https://doi.org/10.1182/blood-2018-06-857714
State	Published - 2019

Access to Document

10.1182/blood-2018-06-857714

Cite this

@article{8857f4f09d9a493a9d017878b897bde2,

title = "Durable remissions with obinutuzumab-based chemoimmunotherapy: Long-term follow-up of the phase 1b GALTON trial in CLL",

author = "Brown, \{Jennifer R.\} and Susan OBrien and Kingsley, \{C. Daniel\} and Herbert Eradat and Pagel, \{John M.\} and Jamie Hirata and Tammy McIver and Rodica Morariu-Zamfir and Kipps, \{Thomas J.\}",

note = "Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL",

year = "2019",

doi = "10.1182/blood-2018-06-857714",

language = "English",

volume = "133",

pages = "990--992",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "9",

}

TY - JOUR

T1 - Durable remissions with obinutuzumab-based chemoimmunotherapy

T2 - Long-term follow-up of the phase 1b GALTON trial in CLL

AU - Brown, Jennifer R.

AU - OBrien, Susan

AU - Kingsley, C. Daniel

AU - Eradat, Herbert

AU - Pagel, John M.

AU - Hirata, Jamie

AU - McIver, Tammy

AU - Morariu-Zamfir, Rodica

AU - Kipps, Thomas J.

N1 - Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

PY - 2019

Y1 - 2019

UR - https://www.scopus.com/pages/publications/85067254172

U2 - 10.1182/blood-2018-06-857714

DO - 10.1182/blood-2018-06-857714

M3 - Letter

C2 - 30593446

SN - 0006-4971

VL - 133

SP - 990

EP - 992

JO - Blood

JF - Blood

IS - 9

ER -

Durable remissions with obinutuzumab-based chemoimmunotherapy: Long-term follow-up of the phase 1b GALTON trial in CLL

Access to Document

Other files and links

Cite this